Phospholipase A2, Lipoprotein Associated (LpPLA2) Antibody – Rabbit Polyclonal

PLA2G7: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PAFAD). An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. Asthmatic individuals affected by this condition may manifest severe respiratory symptoms. Defects in PLA2G7 are a cause of susceptibility to asthma (ASTHMA). The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi. PLA2G7 variants can be a risk factor for the development of asthma and PLA2G7 may act as a modifier gene that modulates the severity of this disease. Defects in PLA2G7 are a cause of susceptibility to atopic hypersensitivity (ATOPY). A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. Belongs to the AB hydrolase superfamily. Lipase family.

Protein type: EC 3.1.1.47; Hydrolase; Lipid Metabolism - ether lipid; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 17|17 B3

Cellular Component: cytoplasm; extracellular region; extracellular space

Molecular Function: 1-alkyl-2-acetylglycerophosphocholine esterase activity; calcium-independent phospholipase A2 activity; hydrolase activity; phospholipid binding

Biological Process: inflammatory response; lipid catabolic process; lipid metabolic process; platelet activating factor metabolic process